Post-approval studies (Phase 4)Study completedNCT01593332
What this trial is testing
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Who this might be right for
DMARD Resistant Rheumatoid Arthritis
Mashhad University of Medical Sciences 44